EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

ARGX

542.8

+0.74%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

Search

Sanofi SA

Closed

SectorHealthcare

102.28 0.55

Overview

Share price change

24h

Current

Min

101.72

Max

103.64

Key metrics

By Trading Economics

Income

-2.3B

499M

Sales

-6.5B

7.6B

P/E

Sector Avg

23.663

73.239

EPS

1.31

Dividend yield

3.7

Profit margin

6.539

Employees

82,878

EBITDA

-3.7B

563M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+13.01% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.70%

3.06%

Next Earnings

24 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-2.2B

129B

Previous open

101.73

Previous close

102.28

News Sentiment

By Acuity

32%

68%

87 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

20 Mar 2025, 06:43 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5 Feb 2025, 13:41 UTC

Earnings

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5 Feb 2025, 07:10 UTC

Earnings

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5 Feb 2025, 06:39 UTC

Earnings

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

26 Mar 2025, 06:19 UTC

Market Talk
Earnings

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 Mar 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 Mar 2025, 09:00 UTC

Top News

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 Mar 2025, 06:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 Mar 2025, 06:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 Mar 2025, 06:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Pay $600M Upfront

20 Mar 2025, 06:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 Mar 2025, 06:00 UTC

Acquisitions, Mergers, Takeovers

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 Mar 2025, 09:33 UTC

Hot Stocks

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 Mar 2025, 23:00 UTC

Top News

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 Mar 2025, 09:50 UTC

Earnings

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 Mar 2025, 09:49 UTC

Earnings

Santander Increased 2024 Cash Payments by 19%

24 Feb 2025, 08:56 UTC

Market Talk
Earnings

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 Feb 2025, 08:30 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19 Feb 2025, 06:35 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 Feb 2025, 06:34 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 Feb 2025, 06:34 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 Feb 2025, 06:33 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 Feb 2025, 06:33 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 Feb 2025, 06:33 UTC

Acquisitions, Mergers, Takeovers

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 Feb 2025, 06:32 UTC

Acquisitions, Mergers, Takeovers

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 Feb 2025, 06:31 UTC

Acquisitions, Mergers, Takeovers

Sanofi, CD&R Sign Opella Share Purchase Agreement

14 Feb 2025, 10:55 UTC

Market Talk
Earnings
Acquisitions, Mergers, Takeovers

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5 Feb 2025, 07:48 UTC

Market Talk
Earnings

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

5 Feb 2025, 06:01 UTC

Earnings

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

5 Feb 2025, 06:01 UTC

Earnings

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

13.01% upside

12 Months Forecast

Average 115.177 EUR  13.01%

High 125 EUR

Low 92 EUR

Based on 13 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

101.1 / 103.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

87 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.